Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
Novartis to License VYGR's Capsid for Gene Therapy in Neurology
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $118
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Perspective Gets FDA Fast Track Status for Radiopharmaceutical VMT101
Erste Group Maintains Novartis AG(NVS.US) With Buy Rating
Novartis (NVS.US) has applied for a market approval in China for a potential blockbuster oral new drug and new indication.
China National Medical Products Administration Center for Drug Evaluation (CDE) official website latest announcement, Novartis (NVS.US) hydrochloride ipocapone capsules new indications for listing application has been accepted.
Novartis Licenses Gene Therapy Component From Voyager
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Express News | Voyager Therapeutics Announces Novartis Licensing Novel Capsid From TRACER Platform For Use In Gene Therapy Targeting Undisclosed Rare Neurologic Disease
Voyager Enters Into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Novartis Cut to Neutral From Buy by Goldman Sachs
Novartis Analyst Ratings
Goldman Sachs Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $121
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Is Novartis AG (NVS) the Best Cancer Stock to Buy Now?
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
Today's Morning Movers and Top Ratings | TSLA, BAC, BA, INTC and More
Novartis Target Cut to $105 From $110 by Jefferies